膀胱癌免疫生物学与结局的性别差异:治疗启示协作综述
该综述基于PubMed文献,评估小鼠模型与临床队列研究中膀胱尿路上皮癌的性别差异。性别相关差异受性激素、膀胱局部免疫群体、肿瘤遗传学和膀胱微生物组影响,在卡介苗免疫治疗反应及肌层浸润性膀胱癌基底亚型富集方面表现突出。患者性别是影响免疫治疗反应的重要考虑因素,证据支持多因素起源。
要点
- 膀胱尿路上皮癌在发病率、病因及膀胱内免疫治疗反应上存在显著性别二态性。
- 性激素、膀胱局部免疫群体、肿瘤遗传学和膀胱微生物组共同影响性别相关差异。
- 女性肌层浸润性膀胱癌肿瘤中基底亚型富集,非肌层浸润性膀胱癌对卡介苗免疫治疗反应存在性别差异。
核心结论
- 证据支持膀胱尿路上皮癌发病率和结局的性别二态性为多因素起源。
- 患者性别是影响免疫治疗反应的一个具有挑战性的考虑因素,值得进一步关注。
研究设计与样本
- 叙述性综述,通过PubMed数据库评估已发表的小鼠模型和临床队列研究。
- 对流行病学、遗传、激素、免疫生理和临床结局的关键发现进行范围综述。
主要发现
- 膀胱尿路上皮癌的性别相关差异受性激素、膀胱局部常驻免疫群体、肿瘤遗传学和膀胱微生物组影响。
- 在非肌层浸润性膀胱癌的卡介苗免疫治疗反应中,性别差异突出。
- 在肌层浸润性膀胱癌中,女性肿瘤显示基底亚型富集。
- 免疫检查点阻断试验的新发现提示女性与男性结局可能存在差异。
临床怎么用
- 在膀胱尿路上皮癌的免疫治疗设计和临床管理中应考虑患者性别因素。
- 需深入理解导致免疫调节治疗反应性别相关差异的遗传和表观遗传因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Urothelial carcinoma of the bladder (UCB) exhibits significant sexual dimorphism in the incidence, etiology, and response to intravesical immunotherapy. Environmental factors such as tobacco use and clinical management issues such as delayed presentation have widely been associated with sex differences in UCB outcomes. Emerging findings from immune checkpoint blockade trials are suggestive of differential outcomes in females compared with males. Sex-specific differences in the way immune system functions and responds to pathogenic insults are well established. As such, an in-depth understanding of the genetic and epigenetic factors contributing to sex-associated differences in response to immunomodulatory therapies is needed urgently for improved management of UCB. OBJECTIVE: To review the associations between patient sex and clinical outcomes, with a focus on the incidence, host intrinsic features, and response to therapies in UCB. EVIDENCE ACQUISITION: Using the PubMed database, this narrative review evaluates published findings from mouse model-based and clinical cohort studies to identify factors associated with sex and clinical outcomes in bladder cancer. A scoping review of the key findings on epidemiology, genetic, hormonal, immune physiology, and clinical outcomes was performed to explore potential factors that could have implications in immunomodulatory therapy design. EVIDENCE SYNTHESIS: Sex-associated differences in UCB incidence and clinical outcomes are influenced by sex hormones, local bladder resident immune populations, tumor genetics, and bladder microbiome. In the context of therapeutic outcomes, sex differences are prominent in response to bacillus Calmette-Guérin immunotherapy used in the treatment of non-muscle-invasive bladder cancer. Similarly, with respect to tumor molecular profiles in muscle-invasive bladder cancer, tumors from females show enrichment of the basal subtype. CONCLUSIONS: Among proposed tumor/host intrinsic factors that may influence response to immune-based therapies, patient sex remains a challenging consideration that deserves further attention. Evidence to date supports a multifactorial origin of sexual dimorphism in the incidence and outcomes of UCB. PATIENT SUMMARY: In this review, we highlight the sex-associated host and tumor intrinsic features that may potentially drive differential disease progression and therapeutic response in urothelial carcinoma of the bladder.
引用
- Koti M, Ingersoll MA, Gupta S, et al. Sex Differences in Bladder Cancer Immunobiology and Outcomes: A Collaborative Review with Implications for Treatment. Eur Urol Oncol. 2020. PMID: 32967818. doi:10.1016/j.euo.2020.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。